Small Pharma Inc. (CVE:DMT – Get Free Report) shares traded down 6.3% during mid-day trading on Friday . The stock traded as low as C$0.15 and last traded at C$0.15. 1,890,765 shares changed hands during mid-day trading, an increase of 538% from the average session volume of 296,159 shares. The stock had previously closed at C$0.16.
Small Pharma Stock Performance
The company has a market cap of C$50.37 million, a PE ratio of -2.14 and a beta of 0.86. The company has a debt-to-equity ratio of 5.95, a quick ratio of 6.28 and a current ratio of 2.63. The stock’s 50-day simple moving average is C$0.15 and its 200 day simple moving average is C$0.15.
About Small Pharma
Small Pharma Inc, a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company's product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Further Reading
- Five stocks we like better than Small Pharma
- What is the Nasdaq? Complete Overview with History
- Why Energy Transfer Stock Could Soar to New Highs in 2025
- Insider Buying Explained: What Investors Need to Know
- 3 Buy-and-Hold Stocks for Long-Term Growth
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Despite Short-Term Risks Freeport McMoran Worth a Look
Receive News & Ratings for Small Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Small Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
